These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 29571082)

  • 1. Long-term survival improvement in oesophageal cancer in the Netherlands.
    van Putten M; de Vos-Geelen J; Nieuwenhuijzen GAP; Siersema PD; Lemmens VEPP; Rosman C; van der Sangen MJC; Verhoeven RHA
    Eur J Cancer; 2018 May; 94():138-147. PubMed ID: 29571082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of survival among neoadjuvant chemoradiation responders, non-responders and patients receiving primary resection for locally advanced oesophageal squamous cell carcinoma: does neoadjuvant chemoradiation benefit all?
    Hsu PK; Chien LI; Huang CS; Hsieh CC; Wu YC; Hsu WH; Chou TY
    Interact Cardiovasc Thorac Surg; 2013 Sep; 17(3):460-6. PubMed ID: 23728085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of neoadjuvant treatment in clinical T2N0M0 oesophageal cancer: results from a retrospective multi-center European study.
    Markar SR; Gronnier C; Pasquer A; Duhamel A; Beal H; Théreaux J; Gagnière J; Lebreton G; Brigand C; Meunier B; Collet D; Mariette C;
    Eur J Cancer; 2016 Mar; 56():59-68. PubMed ID: 26808298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time interval between neoadjuvant chemoradiotherapy and surgery for oesophageal or junctional cancer: A nationwide study.
    van der Werf LR; Dikken JL; van der Willik EM; van Berge Henegouwen MI; Nieuwenhuijzen GAP; Wijnhoven BPL;
    Eur J Cancer; 2018 Mar; 91():76-85. PubMed ID: 29353163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome of neoadjuvant therapies for cancer of the oesophagus or gastro-oesophageal junction based on a national data registry.
    Klevebro F; Lindblad M; Johansson J; Lundell L; Nilsson M
    Br J Surg; 2016 Dec; 103(13):1864-1873. PubMed ID: 27689845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic impact of neoadjuvant chemoradiation in cT3 oesophageal cancer - A propensity score matched analysis.
    Hölscher AH; Bollschweiler E; Bogoevski D; Schmidt H; Semrau R; Izbicki JR
    Eur J Cancer; 2014 Nov; 50(17):2950-7. PubMed ID: 25307749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determinants in decision making for curative treatment and survival in patients with resectable oesophageal cancer in the Netherlands: a population-based study.
    Koëter M; van Steenbergen LN; Lemmens VE; Rutten HJ; Roukema JA; Nieuwenhuijzen GA
    Cancer Epidemiol; 2015 Dec; 39(6):863-9. PubMed ID: 26651448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Lymph Node Yield on Overall Survival in Patients Treated With Neoadjuvant Chemoradiotherapy Followed by Esophagectomy for Cancer: A Population-based Cohort Study in the Netherlands.
    Visser E; van Rossum PSN; Ruurda JP; van Hillegersberg R
    Ann Surg; 2017 Nov; 266(5):863-869. PubMed ID: 28742691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.
    Haisley KR; Hart KD; Nabavizadeh N; Bensch KG; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
    Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Non-metastatic oesophageal cancer: diagnosis and treatment].
    Voeten DM; den Bakker CM; Goedegebuure RSA; Heineman DJ; Daams F; van der Peet DL
    Ned Tijdschr Geneeskd; 2019 Sep; 163():. PubMed ID: 31556490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. International benchmarking in oesophageal and gastric cancer surgery.
    Busweiler LAD; Jeremiasen M; Wijnhoven BPL; Lindblad M; Lundell L; van de Velde CJH; Tollenaar RAEM; Wouters MWJM; van Sandick JW; Johansson J; Dikken JL
    BJS Open; 2019 Feb; 3(1):62-73. PubMed ID: 30734017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
    Shapiro J; van Lanschot JJB; Hulshof MCCM; van Hagen P; van Berge Henegouwen MI; Wijnhoven BPL; van Laarhoven HWM; Nieuwenhuijzen GAP; Hospers GAP; Bonenkamp JJ; Cuesta MA; Blaisse RJB; Busch ORC; Ten Kate FJW; Creemers GM; Punt CJA; Plukker JTM; Verheul HMW; Bilgen EJS; van Dekken H; van der Sangen MJC; Rozema T; Biermann K; Beukema JC; Piet AHM; van Rij CM; Reinders JG; Tilanus HW; Steyerberg EW; van der Gaast A;
    Lancet Oncol; 2015 Sep; 16(9):1090-1098. PubMed ID: 26254683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of recurrence in early-stage oesophageal cancer after chemoradiotherapy and surgery compared with surgery alone.
    Robb WB; Messager M; Dahan L; Mornex F; Maillard E; D'Journo XB; Triboulet JP; Bedenne L; Seitz JF; Mariette C; ; ; ; ;
    Br J Surg; 2016 Jan; 103(1):117-25. PubMed ID: 26511668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Definitive or neoadjuvant chemoradiotherapy for squamous cell oesophageal cancer?
    Ilson D; Lordick F
    Lancet Oncol; 2018 Oct; 19(10):1285-1286. PubMed ID: 30528077
    [No Abstract]   [Full Text] [Related]  

  • 15. Increasing the interval between neoadjuvant chemoradiotherapy and surgery in esophageal cancer: a meta-analysis of published studies.
    Lin G; Han SY; Xu YP; Mao WM
    Dis Esophagus; 2016 Nov; 29(8):1107-1114. PubMed ID: 26542065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
    Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ
    Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patients' preferences for treatment after neoadjuvant chemoradiotherapy for oesophageal cancer.
    Noordman BJ; de Bekker-Grob EW; Coene PPLO; van der Harst E; Lagarde SM; Shapiro J; Wijnhoven BPL; van Lanschot JJB
    Br J Surg; 2018 Nov; 105(12):1630-1638. PubMed ID: 29947418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-treatment maximal oesophageal wall thickness is independently associated with response to chemoradiotherapy in patients with T3-4 oesophageal squamous cell carcinoma.
    Li SH; Rau KM; Lu HI; Wang YM; Tien WY; Liang JL; Lin WC
    Eur J Cardiothorac Surg; 2012 Dec; 42(6):958-64. PubMed ID: 22466694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased incidence and survival for oesophageal cancer but not for gastric cardia cancer in the Netherlands.
    Dikken JL; Lemmens VE; Wouters MW; Wijnhoven BP; Siersema PD; Nieuwenhuijzen GA; van Sandick JW; Cats A; Verheij M; Coebergh JW; van de Velde CJ
    Eur J Cancer; 2012 Jul; 48(11):1624-32. PubMed ID: 22317953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variations among 5 European countries for curative treatment of resectable oesophageal and gastric cancer: A survey from the EURECCA Upper GI Group (EUropean REgistration of Cancer CAre).
    Messager M; de Steur WO; van Sandick JW; Reynolds J; Pera M; Mariette C; Hardwick RH; Bastiaannet E; Boelens PG; van deVelde CJ; Allum WH;
    Eur J Surg Oncol; 2016 Jan; 42(1):116-22. PubMed ID: 26461256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.